Literature DB >> 2979216

SMS 201-995 treatment and advanced intestinal cancer: a pilot study.

A P Savage1, J Calam, C B Wood, S R Bloom.   

Abstract

The hypothesis that somatostatin, a compound with antitrophic effects on the gastrointestinal tract, may affect beneficially the progression of advanced intestinal cancer has been tested in a small pilot study. Ten patients, four with advanced pancreatic cancer, four with advanced colorectal cancer and two with gastric cancer, were treated with a long-acting analogue of somatostatin, SMS 201-995, 50, 100 micrograms subcutaneously twice daily. There were no clinical, radiological or biochemical indicators of a response to this treatment. There are no indications from this study that hormonal manipulation alters the rate of growth of advanced gastrointestinal cancer.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2979216     DOI： 10.1111/j.1365-2036.1987.tb00612.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


  5 in total

Review 1.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.

Authors:  S Y Iftikhar; S A Watson; D L Morris
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

3.  Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer.

Authors:  Katalin Leiszter; Ferenc Sipos; Orsolya Galamb; Tibor Krenács; Gábor Veres; Barna Wichmann; István Fűri; Alexandra Kalmár; Árpád V Patai; Kinga Tóth; Gábor Valcz; Zsolt Tulassay; Béla Molnár
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

4.  A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.

Authors:  S Cascinu; E Del Ferro; G Catalano
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

5.  Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.

Authors:  S I Helle; J Geisler; J P Poulsen; K Hestdal; K Meadows; W Collins; K M Tveit; J M Holly; P E Lønning
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.